NCT02556463 - A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2015

Primary Completion Date

October 26, 2018

Study Completion Date

October 26, 2018

Conditions

Solid TumorsCTCLCancer

Interventions

DRUG

MEDI9197

Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)

BIOLOGICAL

durvalumab

Subjects will receive durvalumab every 4 weeks

Trial Locations (10)

Research Site, New York

Research Site, Philadelphia

Research Site, Minneapolis

Research Site, St Louis

Research Site, Houston

Research Site, Aurora

Research Site, San Francisco

Research Site, Villejuif

Research Site, Chapel Hill

Research Site, Toronto